Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results

Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth
                 Quarter and Year-End 2013 Financial Results

Conference Call and Webcast Scheduled For Thursday, February 6, 2014

PR Newswire

SAN DIEGO, Feb. 4, 2014

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:
NBIX) announced today that the Company will report its fourth quarter and
year-end 2013 financial results after the Nasdaq market closes on Thursday,
February 6, 2014. Neurocrine will then host a live conference call and
webcast to discuss its financial results and provide a Company update Thursday
afternoon, February 6, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific

Participants can access the live conference call by dialing 800-862-9098 (US)
or 785-424-1051 (International) using the conference ID: NBIX. The call can
also be accessed via the webcast through the Company's website at

If you are unable to attend the webcast and would like further information on
this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600. A replay of the conference call
will be available approximately one hour after the conclusion of the call by
dialing 800-723-8184 (US) or 402-220-2668 (International) using the conference
ID: NBIX. The call will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company
primarily focused on neurological and endocrine based diseases and disorders.
The Company discovers and develops innovative pharmaceuticals, in diseases
with high unmet medical needs or where the existing drug classes are
inadequate, through a disciplined yet entrepreneurial process. Utilizing a
portfolio approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development. Neurocrine's
two lead late stage clinical programs are elagolix, a GnRH antagonist for
women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2
inhibitor for the treatment of movement disorders. Neurocrine intends to
maintain certain commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the internet at

SOURCE Neurocrine Biosciences, Inc.

Contact: Neurocrine Biosciences Investor Relations, +1-858-617-7600
Press spacebar to pause and continue. Press esc to stop.